Alpha DNA Investment Management LLC Makes New $552,000 Investment in Hims & Hers Health, Inc. (NYSE:HIMS)

Alpha DNA Investment Management LLC bought a new stake in Hims & Hers Health, Inc. (NYSE:HIMS) in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm bought 29,986 shares of the company’s stock, valued at approximately $552,000.

A number of other institutional investors and hedge funds also recently made changes to their positions in HIMS. Nisa Investment Advisors LLC boosted its holdings in Hims & Hers Health by 679.2% in the second quarter. Nisa Investment Advisors LLC now owns 1,839 shares of the company’s stock valued at $37,000 after acquiring an additional 1,603 shares during the last quarter. Quest Partners LLC lifted its position in Hims & Hers Health by 5,944.1% during the 2nd quarter. Quest Partners LLC now owns 3,566 shares of the company’s stock valued at $72,000 after purchasing an additional 3,507 shares during the period. CWM LLC boosted its stake in shares of Hims & Hers Health by 21.4% in the 3rd quarter. CWM LLC now owns 5,982 shares of the company’s stock valued at $110,000 after purchasing an additional 1,054 shares during the last quarter. Van ECK Associates Corp acquired a new stake in shares of Hims & Hers Health during the 2nd quarter worth approximately $111,000. Finally, Amalgamated Bank raised its stake in shares of Hims & Hers Health by 55.9% during the second quarter. Amalgamated Bank now owns 6,566 shares of the company’s stock worth $133,000 after buying an additional 2,354 shares during the last quarter. Institutional investors own 63.52% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities analysts have issued reports on the stock. Deutsche Bank Aktiengesellschaft raised their price objective on shares of Hims & Hers Health from $23.00 to $27.00 and gave the company a “hold” rating in a research note on Wednesday, November 6th. Canaccord Genuity Group lifted their price objective on Hims & Hers Health from $24.00 to $28.00 and gave the stock a “buy” rating in a research note on Tuesday, November 5th. Bank of America downgraded Hims & Hers Health from a “buy” rating to an “underperform” rating and dropped their price objective for the company from $32.00 to $18.00 in a report on Thursday, November 14th. Piper Sandler restated a “neutral” rating and set a $21.00 target price (up previously from $18.00) on shares of Hims & Hers Health in a report on Tuesday, November 5th. Finally, Needham & Company LLC began coverage on Hims & Hers Health in a research note on Thursday, August 22nd. They issued a “buy” rating and a $24.00 price target for the company. One investment analyst has rated the stock with a sell rating, eight have assigned a hold rating and seven have issued a buy rating to the stock. Based on data from MarketBeat, Hims & Hers Health currently has a consensus rating of “Hold” and a consensus price target of $20.71.

Hims & Hers Health Stock Up 4.9 %

Shares of HIMS stock opened at $25.33 on Friday. The company has a market capitalization of $5.53 billion, a price-to-earnings ratio of 57.57 and a beta of 1.06. Hims & Hers Health, Inc. has a 12-month low of $8.02 and a 12-month high of $30.44. The firm has a fifty day moving average of $20.55 and a 200-day moving average of $19.26.

Hims & Hers Health (NYSE:HIMS) last released its quarterly earnings results on Monday, November 4th. The company reported $0.32 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.06 by $0.26. The firm had revenue of $401.56 million for the quarter, compared to the consensus estimate of $382.20 million. Hims & Hers Health had a return on equity of 10.97% and a net margin of 8.19%. The company’s revenue for the quarter was up 77.1% on a year-over-year basis. During the same quarter last year, the business posted ($0.04) EPS. On average, equities analysts expect that Hims & Hers Health, Inc. will post 0.29 EPS for the current year.

Insiders Place Their Bets

In related news, insider Soleil Boughton sold 2,345 shares of Hims & Hers Health stock in a transaction dated Tuesday, September 3rd. The stock was sold at an average price of $14.65, for a total value of $34,354.25. Following the sale, the insider now owns 159,796 shares of the company’s stock, valued at approximately $2,341,011.40. The trade was a 1.45 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, COO Melissa Baird sold 58,750 shares of the stock in a transaction that occurred on Monday, November 18th. The shares were sold at an average price of $21.04, for a total value of $1,236,100.00. Following the transaction, the chief operating officer now directly owns 630,166 shares of the company’s stock, valued at $13,258,692.64. This trade represents a 8.53 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 1,056,183 shares of company stock valued at $21,501,682 in the last quarter. 17.71% of the stock is currently owned by insiders.

Hims & Hers Health Profile

Hims & Hers Health, Inc operates a telehealth platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers.